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tology Forum and the World Allergy Organization. Patients 
with CSU (evaluated at urticaria diagnosis) and patients 
without CSU (evaluated at the last visit) were assessed for 
lupus clinical/laboratory features and treatment.  Results: 
CSU was observed in 10/852 cSLE patients (1.17%). The me-
dian of cSLE duration at urticaria diagnosis was 0 (–3 to 5) 
years. Comparison of cSLE patients with and without CSU 
revealed a greater frequency of constitutional symptoms (40 
vs. 8%, p = 0.006), reticuloendothelial system involvement 
(30 vs. 3%, p = 0.003), mucocutaneous (90 vs. 28%, p < 0.0001) 
and musculoskeletal manifestations (50 vs. 6%, p < 0.0001) 
and methylprednisolone pulse therapy use (60 vs. 9%, p < 
0.0001) in the former group. The frequency of immunosup-
pressive treatment was lower in patients with CSU (p  = 
0.018). The median SLE Disease Activity Index 2000 (12 vs. 2, 
p  < 0.0001) and erythrocyte sedimentation rate (40 vs. 19 
mm/1st hour, p = 0.024), was higher in patients with CSU. 
Conclusions: To our knowledge, this is the first study with 
evidence that CSU may be linked to cSLE. We also demon-
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 Abstract 
 Background: Data regarding the prevalence of chronic 
spontaneous urticaria (CSU) in childhood-onset systemic lu-
pus erythematosus (cSLE) patients and possible associated 
factors are limited to a few case reports. The objectives of this 
study were to assess CSU in a large cSLE population, in order 
to evaluate the demographic data, clinical manifestations, 
disease activity/damage, laboratory abnormalities and treat-
ment. Methods: A retrospective multicenter cohort study 
(Brazilian cSLE group) was performed in 10 Pediatric Rheu-
matology services and included 852 cSLE patients. CSU was 
diagnosed according to the guidelines of the European 
Academy of Allergy and Clinical Immunology, the Global Al-
lergy and Asthma European Network, the European Derma-
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strated that this particular skin manifestation occurs pre-
dominantly at disease onset and is associated with lupus 
moderate/high disease activity without major organ in-
volvement.  © 2015 S. Karger AG, Basel 
 Introduction 
 Childhood-onset systemic lupus erythematosus 
(cSLE) is a rare autoimmune disorder that may affect 
multiple organs and systems  [1, 2] . The mucocutaneous 
involvement has been reported in approximately 70% of 
these patients  [1, 3, 4] .
 Indeed, a variety of cutaneous manifestations can be 
observed in lupus patients  [1, 3, 4] , including urticaria 
 [5–8] . This skin involvement is defined by the sudden on-
set of wheals, angioedema or both. Wheals are character-
ized by evanescent lesions, with central swelling of vari-
able size usually surrounded by a reflex erythema, and 
associated with an itching or burning sensation  [9] .
 A previous study found that patients with chronic ur-
ticaria have a higher incidence of SLE in the adult popula-
tion, but a systematic evaluation of disease parameters 
was not performed  [5] . Few case reports have evaluated 
urticaria either in adult cSLE patients  [6–8] . However, the 
prevalence of this manifestation in the pediatric lupus 
population and the possible associated factors have not 
been studied.
 Therefore, the objective of this study was to assess 
chronic spontaneous urticaria (CSU) in a large cSLE pop-
ulation, and to evaluate demographic data, clinical mani-
festations, disease activity, cumulative disease damage, 
laboratory abnormalities and treatment.
 Materials and Methods 
 Study Procedure and Patient Selection 
 This was a retrospective, multicenter cohort study (Brazilian 
cSLE group) including 1,017 cSLE patients followed in 10 Pediatric 
Rheumatology tertiary referral services in São Paulo State, Brazil. 
One hundred and sixty-five patients were excluded due to incom-
plete medical charts (n = 96), undifferentiated connective tissue dis-
order with  ≤ 3 American College of Rheumatology (ACR) criteria 
(n = 43), isolated cutaneous lupus erythematosus (n = 11), neonatal 
lupus erythematosus (n = 8), drug-induced lupus (n = 5) and other 
autoimmune diseases (n = 2). None of the patients had urticaria vas-
culitis, hypocomplementemic urticaria vasculitis syndrome or ma-
lignancies. Therefore, the study group comprised 852 cSLE patients. 
All patients fulfilled the ACR lupus criteria  [10] , with disease onset 
before 18 years of age  [11] and current age of  ≤ 25 years. The Com-
mittee for Research Ethics of each center approved the study.
 An investigator meeting was held for this study on the 29 
 September 2012 in São Paulo city to define the protocol and stan-
dardize clinical, laboratory and treatment parameters definition, 
disease activity and damage-tools scoring. Data collection training 
was conducted locally by investigators in each center and a unique 
database was built up (by M.P.L.F. and M.F.C.S.). Data discrep-
ancy was sorted out by  ≥ 1 rounds of queries for accuracy. Data 
were collected between November 2012 and October 2014.
 Patient’s medical charts were carefully reviewed according to 
an extensive standardized protocol for demographic data, clinical 
features, laboratory findings, therapeutic data, outcomes and CSU 
characteristics. Patients with CSU (evaluated at urticaria diagno-
sis) and patients without CSU (evaluated at the last visit) were di-
vided in 2 groups and assessed for the clinical, laboratory and treat-
ment features of lupus.
 CSU was diagnosed according to the dermatology section of 
the guidelines of the European Academy of Allergy and Clinical 
Immunology, the EU-funded Network of Excellence, the Global 
Allergy and Asthma European Network, the European Dermatol-
ogy Forum and the World Allergy Organization, and defined as 
the spontaneous appearance of at least one manifestation, i.e. a 
wheal and/or angioedema that lasted for  ≥ 6 weeks, excluding in-
ducible urticaria  [9] . We evaluated the total urticaria duration 
(from onset of wheals to complete resolution), the time between 
urticaria onset and cSLE diagnosis, the distribution of wheals, the 
presence of angioedema, painful lesions, current allergies (rhinitis 
and asthma), a family history of atopic diseases and current infec-
tions. Eosinophilia (>500 eosinophils/mm 3 ) and elevated levels of 
serum IgE (>200 IU/ml) were also evaluated.
 Demographic Data, Clinical Evaluation, Disease Activity and 
Damage and Therapies 
 Demographic data included gender, race, current age, age at 
cSLE onset and disease duration. SLE clinical manifestations were 
defined as: constitutional symptoms (fever and weight loss), in-
volvement of the reticuloendothelial system (adenomegaly, hepa-
tomegaly and splenomegaly), mucocutaneous lesions (malar or 
discoid rash, photosensitivity, nasal or oral ulcers, alopecia and 
cutaneous vasculitis, i.e. ulceration, periungueal infarction or 
splinter hemorrhage), musculoskeletal involvement (nonerosive 
arthritis and myositis), serositis (pleuritis and pericarditis), ne-
phritis (proteinuria  ≥ 0.5 g/24 h, the presence of cellular casts, per-
sistent hematuria  ≥ 5 red blood cells/high-power field and/or per-
sistent leukocituria  ≥ 5 leukocytes/high-power field), hematologic 
abnormalities, i.e. autoimmune hemolytic anemia, leukopenia (a 
white blood cell count <4,000/mm 3 ), lymphopenia (lymphocytes 
<1,500/mm 3 ) and thrombocytopenia (a platelet count <100,000/
mm 3 ) on two or more occasions in the absence of drugs or infec-
tion. Neuropsychiatric lupus included 19 syndromes according to 
ACR classification criteria  [12] . Hypothyroidism was defined as 
reduced free thyroxine (T 4 ) and elevated thyroid-stimulating hor-
mone (TSH) levels, and subclinical hypothyroidism as elevated 
TSH associated with normal T 4 . The presence of antithyroid anti-
bodies, i.e. antithyroid peroxidase, antithyroglobulin and anti-
TSH receptor antibody, and hypothyroidism was necessary for a 
diagnosis of autoimmune thyroiditis  [13] . Antiphospholipid syn-
drome was diagnosed according to the presence of arterial and/or 
venous thrombosis and antiphospholipid antibodies  [14] .
 High blood pressure was defined as systolic and/or diastolic 
blood pressures  ≥ 95th percentile for gender, age and height on  ≥ 3 
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occasions  [15] . Acute kidney injury was determined by a sudden 
increase in serum creatinine >2 mg/dl  [16] or by modified RIFLE 
(risk, injury, failure, loss of kidney function and end-stage kidney 
disease) criteria  [17] . Chronic renal disease was defined as struc-
tural or functional abnormalities of the kidney for  ≥ 3 months (with 
or without a decreased glomerular filtration rate) or a glomerular 
filtration rate <60 ml/min/1.73 m 2 for  ≥ 3 months  [18] .
 Laboratorial assessment included the erythrocyte sedimenta-
tion rate, C-reactive protein, a complete blood cell count, serum 
urea and creatinine, urinalysis and 24-hour urine protein excre-
tion. Complement levels (CH50, C3 and C4) and anti-double-
stranded DNA autoantibodies were carried out at each of the cen-
ters involved and the cut off values were considered valid. SLE 
disease activity and cumulative damage were scored according to 
the SLE Disease Activity Index 2000 (SLEDAI-2K)  [19] , which 
may range from 0 to 105, and the Systemic Lupus International 
Collaborating Clinics/ACR-Damage Index  [20] , which may range 
from 0 to 47, respectively.
 Current therapy (prednisone, intravenous methylprednisolone 
pulse, chloroquine diphosphate, hydroxychloroquine sulfate, 
methotrexate, azathioprine, cyclosporine, mycophenolate, intra-
venous cyclophosphamide, intravenous gammaglobulin and 
rituximab) was also recorded.
 Statistical Analysis 
 Results are presented as number (%) for categorical variables 
and median (range) for continuous variables. Comparisons of cat-
egorical variables were assessed by the Fisher exact test. Continu-
ous variables from cSLE patients with and without CSU were com-
pared with the Mann-Whitney test. The significance levels of the 
independent variables were set at 5% (p < 0.05).
 Results 
 CSU was observed in 10/852 cSLE patients (1.17%) with 
a median of total urticaria duration of 190 days (44–760 
days). The median cSLE duration at urticaria diagnosis was 
0 (–3 to 5) years and the age at urticaria onset was 13 (7–17) 
years. Isolated CSU was observed in 2 cSLE patients before 
lupus diagnosis, at diagnosis in 5 and after diagnosis in 3. 
Wheals were present in all of the 10 cSLE patients and an-
gioedema was observed in 3. Wheal distribution was dif-
fuse (trunk, upper/lower limbs and/or face) in 9 and in the 
lower limbs in 1. None of them had painful lesions, acute/
chronic infections or helminthic parasitic infections. Cur-
rent allergies were reported in 4/10 patients: rhinitis in 2 
and asthma in 2. A family history of atopic diseases was 
observed in 3/10 patients. Eosinophilia was evident in 1/10 
with no allergy spectrum. IgE was available in 5/10 cSLE 
patients and an elevated serum IgE level was observed in 
1/5 cSLE patients without asthma or rhinitis. Moderate dis-
ease activity, at least (SLEDAI-2K  ≥ 6), was observed in 
100%. Medications used for CSU included H1-antihista-
mines and glucocorticoids for 2 patients who developed 
CSU before cSLE diagnosis. The other patients presenting 
with CSU at or after lupus diagnosis were treated with H1-
antihistamines (60%), glucocorticoids (100%), antimalari-
als (80%) and immunosuppressive agents (20%).  Table 1 
shows CSU characteristics in cSLE patients.
 Demographic data, clinical manifestations and disease 
activity/damage scores in 852 cSLE patients according to 
the presence of CSU are shown in  table 2 . The compari-
son of cSLE patients with and without CSU revealed 
greater frequency of constitutional symptoms (40 vs. 8%, 
p = 0.006), reticuloendothelial system involvement (30 vs. 
3%, p  = 0.003) and mucocutaneous (90 vs. 28%, p  < 
0.0001) and musculoskeletal manifestations (50 vs. 6%, 
p < 0.0001). The median SLEDAI-2K (12 vs. 2, p < 0.0001) 
was also significantly greater in patients with CSU. Dis-
ease damage (current Systemic Lupus International Col-
 Table 1.  CSU characteristics in cSLE patients
Characteristics Patient No.
1 2 3 4 5 6 7 8 9 10
Age at CSU onset, years 13.1 10.7 10.2 13.2 17.1 16.2 7.1 8.7 13.8 15.7
Disease duration until CSU, months –36 0 –6 7 1 0 0 0 61 0
Total duration of CSU, days 65 60 272 270 140 240 720 140 44 760
Angioedema yes no no no no yes no no no yes
Allergic asthma yes no no no no no no no yes no
Allergic rhinitis no no yes no no yes no no no no
Autoimmune thyroiditis yes no no no no no yes no no no












 AH = H1-antihistamines; AM = antimalarials; Aza = azathioprine; CE = corticosteroids; Mtx = methotrexate.
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laborating Clinics/ACR-Damage Index value) was simi-
lar in the 2 groups (p = 0.740;  table 2 ).
 Laboratory characteristics and treatment of 852 cSLE 
according to the presence of CSU are illustrated in  table 3 . 
The median erythrocyte sedimentation rate (40 vs. 19 
mm/1st hour, p = 0.024) and current prednisone dose in 
mg/day (30 vs. 11.2, p = 0.010) and in mg/kg/day (0.89 vs. 
0.22, p < 0.0001) were significantly higher in patients with 
CSU than in without urticaria. The use of methylpred-
nisolone pulse therapy (60 vs. 9%, p < 0.0001) was sig-
nificantly greater in the former group. The frequency of 
immunosuppressive treatment was lower in patients with 
CSU (20 vs. 61%, p = 0.018;  table 3 ).
 Further analysis of associated diseases demonstrated 
that autoimmune thyroiditis was evident in 2/10 of CSU 
cSLE patients (20%) compared to 30/806 without CSU 
(4%, p = 0.055). No case of antiphospholipid syndrome 
was observed in the former group (0 vs. 5%, p = 1.0).
 Table 2.  Demographic data, clinical manifestations and disease activity/damage scores in 852 cSLE patients at 







Female gender (n = 852) 8/10 (80) 724/842 (86) 0.639
Caucasian (n = 830) 8/10 (80) 584/820 (71) 0.733
Age at cSLE onset, years (n = 846) 11.62 (7.1–17) 11.87 (0.25–17.83) 0.554
Clinical manifestations
Constitutional features (n = 848) 4/10 (40) 64/838 (8) 0.006
Fever (n = 848) 2/10 (20) 47/838 (6) 0.109
Weight loss (n = 823) 3/10 (30) 27/813 (3) 0.004
Reticuloendothelial system involvement (n = 848) 3/10 (30) 23/838 (3) 0.003
Lymphadenopathy (n = 847) 2/10 (20) 11/837 (1) 0.009
Hepatomegaly (n = 848) 1/10 (10) 17/838 (2) 0.194
Splenomegaly (n = 848) 0/10 (0) 6/838 (1) 1.000
Mucocutaneous involvement (n = 850) 9/10 (90) 239/840 (28) <0.0001
Malar rash (n = 847) 6/10 (60) 114/837 (14) 0.001
Discoid rash (n = 849) 0/10 (0) 12/839 (1) 1.000
Photosensitivity (n = 850) 8/10 (80) 107/840 (13) <0.0001
Mucosal ulcers (n = 849) 1/10 (10) 35/839 (4) 0.353
Alopecia (n = 849) 4/10 (40) 63/839 (7) 0.005
Cutaneous vasculitis (n = 848) 4/10 (40) 52/838 (6) 0.003
Musculoskeletal involvement (n = 850) 5/10 (50) 52/840 (6) <0.0001
Arthritis (n = 849) 4/10 (40) 47/839 (6) 0.002
Myositis (n = 849) 1/10 (10) 6/839 (1) 0.080
Serositis (n = 850) 0/10 (0) 13/840 (1) 1.000
Pleuritis (n = 848) 0/10 (0) 11/838 (1) 1.000
Pericarditis (n = 848) 0/10 (0) 11/838 (1) 1.000
Neuropsychiatric involvement (n = 850) 1/10 (10) 68/840 (8) 0.573
Central nervous system (n = 847) 1/10 (10) 67/837 (8) 0.569
Peripheral nervous system (n = 844) 0/10 (0) 4/834 (0) 1.000
Nephritis (n = 830) 3/10 (30) 165/820 (20) 0.432
Other
Arterial hypertension (n = 842) 1/10 (10) 108/832 (13) 1.000
Acute renal failure (n = 841) 0/10 (0) 31/831 (4) 1.000
Chronic renal failure (n = 841) 0/10 (0) 25/831 (3) 1.000
Disease activity/damage
SLEDAI-2K (n = 753) 12 (4–24) 2 (0–45) <0.0001
SLICC/ACR-DI (n = 770) 0 (0–1) 0 (0–9) 0.740
 Results are presented as n (%) or median (range). SLICC/ACR-DI = Systemic Lupus International Collabo-
rating Clinics/ACR – Damage Index.




 To our knowledge, this is the first study with evidence 
that CSU may be linked to cSLE patients and associated 
with moderate/high disease activity.
 The strength of this multicentric study was the large 
sample size of the cSLE population followed at 10 univer-
sity services in São Paulo State, Brazil, as well as the use 
of a standardized database to minimize bias. The CSU 
definition was based on international consensus  [9] . Dis-
eases related to urticaria/angioedema were excluded, par-
ticularly urticaria vasculitis and hypocomplementemic 
urticaria vasculitis syndrome  [21–23] , since these abnor-
malities are associated with localized, nonblanching, 
painful lesions  [23] which persist for >24 h and leave 
brownish residues when healed  [22] .
 The main weakness of the study was the retrospective 
design with possible missing data. An evaluation of auto-
immune markers associated with CSU, such as an autolo-
gous serum skin test or circulating functional autoanti-
bodies (directed against IgE or high-affinity IgE recep-
tor  – FcεRI), was not performed  [24–27] , and an IgE 
measurement was not available for all patients with CSU. 
Cryopyrin-associated periodic syndromes and hereditary 
or acquired C1 esterase inhibitor deficiency were also not 
systematically evaluated.
 Table 3.  Laboratory characteristics and treatment of 852 cSLE patients at CSU diagnosis compared to the patients 







ESR, mm/1st hour, (n = 709) 40 (15–95) 19 (1–135) 0.024
CRP, mg/dl (n = 551) 1.79 (0–14) 0.7 (0–404) 0.320
Autoimmune hemolytic anemia (n = 825) 0/10 (0) 26/815 (3) 1.000
Leukopenia <4,000/mm3 (n = 788) 1/10 (10) 62/778 (8) 0.568
Lymphopenia <1,500/mm3 (n = 788) 3/10 (30) 138/778 (18) 0.396
Thrombocytopenia, <150,000/mm3 (n = 793) 0/10 (0) 37/783 (5) 1.000
Hematuria (n = 755) 3/10 (30) 133/745 (18) 0.398
Cilindruria (n = 746) 0/10 (0) 27/736 (4) 1.000
Proteinuria (n = 641) 1/10 (10) 149/631 (24) 0.466
Low C3, C4 and/or CH50 (n = 617) 5/8 (62) 271/609 (44) 0.477
Anti-double-stranded DNA (n = 718) 3/10 (30) 265/708 (37) 0.751
Treatment
Nonsteroidal anti-inflammatory drugs (n = 840) 0/10 (0) 46/830 (5) 1.000
Glucocorticosteroids
Prednisone (n = 842) 10/10 (100) 655/832 (79) 0.132
Current dose, mg/day (n = 665) 30 (1–60) 11.2 (1–90) 0.010
mg/kg/day (n = 644) 0.89 (0.35–1.2) 0.22 (0.02–10) <0.0001
Methylprednisolone pulse therapy (n = 838) 6/10 (60) 71/828 (9) <0.0001
Antimalarial drugs (n = 839) 8/10 (80) 558/829 (67) 0.513
Chloroquine diphosphate (n = 814) 2/10 (20) 129/804 (16) 0.667
Hydroxychloroquine sulfate (n = 816) 6/10 (60) 444/806 (55) 1.000
Immunosuppressive agents (n = 843) 2/10 (20) 505/833 (61) 0.018
Azathioprine (n = 840) 1/10 (10) 287/830 (35) 0.178
Cyclosporine (n = 843) 0/10 (0) 30/833 (4) 1.000
Methotrexate (n = 842) 1/10 (10) 70/832 (8) 0.588
Mycophenolate mofetil (n = 843) 0/10 (0) 117/833 (14) 0.373
Cyclophosphamide (n = 842) 0/10 (0) 45/832 (5) 1.000
Other
Intravenous immunoglobulin (n = 842) 0/10 (0) 14/832 (2) 1.000
Rituximab (n = 841) 0/10 (0) 1/831 (0) 1.000
 Results are presented as n (%) or median (range). CRP = C-reactive protein; ESR = erythrocyte sedimentation 
rate.
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 Other autoimmune disorders have been associated 
with CSU, including dermatomyositis, polymyositis, 
Sjögren syndrome and juvenile idiopathic arthritis  [28] . 
We describe a low frequency of CSU in a large population 
of cSLE patients. Of note, the majority of cSLE patients 
presented this skin manifestation before or at disease on-
set, as was also observed previously in case reports of 
adult and cSLE patients  [6, 8] .
 Interestingly, our study indicated that CSU may be 
linked to active cSLE, with a predominance of constitu-
tional, mucocutaneous and musculoskeletal involve-
ment, without a high frequency of severe lupus manifes-
tations.
 We also evaluated antithyroid antibodies, which are 
the most common autoantibodies reported in adults (14–
33%) and children (4.3%) with chronic urticaria  [5, 24, 
29–32] . Twenty percent of the cSLE patients with CSU 
evaluated had autoimmune thyroid disease; this contrasts 
with the 7% of this endocrine abnormality previously re-
ported in a cohort study regarding the overall cSLE popu-
lation at a single center  [13] . The pathophysiology of this 
disorder is unknown, but the immune dysregulation may 
be related to autoimmunity or to chronic inflammatory 
processes  [5] .
 The frequency of CSU in cSLE is within the expected 
range reported in other populations of children and 
 adolescents (0.1–3%)  [31, 33] . There are, however, no 
systematic studies regarding the prevalence of CSU 
in  the Brazilian pediatric population. In addition, the 
analysis of the influence of race was hampered by the 
small representation of non-Caucasian patients in our 
sample.
 CSU may be triggered by lupus treatment medications, 
particularly nonsteroidal anti-inflammatory drugs  [9, 28, 
29] , but none of our patients was under this therapy at 
CSU onset. The majority of cSLE patients were treated 
with H1-antihistamines, according to the literature rec-
ommendations  [28, 29] . Moderate glucocorticoid dose 
and/or intravenous methylprednisolone pulse were re-
quired to treat our lupus patients with CSU and the ma-
jority did not need immunosuppressive agents.
 In conclusion, urticaria was linked to early cSLE. We 
also demonstrated that this skin manifestation is associ-
ated with lupus moderate/high disease activity without 
major organ involvement.
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